Image of lluminated lightbulb being held by both a doctor and patient

Endometrial cancer ILLUMINATED

Introducing JEMPERLI (dostarlimab), the first licensed monotherapy immunotherapy for recurrent/advanced dMMR/MSI-H endometrial cancer1

JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.1

Want to discover more about how JEMPERLI can support your patients?

Footnotes

dMMR, mismatch repair deficient; EC, endometrial cancer; MSI-H, microsatellite instability-high.

References

  1. JEMPERLI (dostarlimab) Summary of Product Characteristics.

Adverse events should be reported.
Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/ (UK) or search for MHRA Yellow Card in the Google Play or Apple App store.

Adverse events should also be reported to GSK Limited on 0800 221 441 or uksafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

July 2022 ӏ PM-GB-DST-WCNT-220001 (V2.0)